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ABSTRACT
Objective: The aim was to examine statin
discontinuation rates in a cohort of elderly Australians
with newly diagnosed cancer using population-based
secondary health data.
Design: Observational cohort study.
Setting: New South Wales, the largest jurisdiction in
Australia. The Pharmaceutical Beneﬁts and
Repatriation Pharmaceutical Beneﬁts Schemes are
national programmes subsidising prescription drugs to
the Australian population and Australian Government
Department of Veterans’ Affairs clients.
Participants: The cohort comprised 1731 cancer
patients aged $65 years with evidence of statin use in
the 90 days prior to diagnosis. They were matched to
3462 non-cancer patients prescribed statins in the
same period.
Main outcome measure: The authors compared
statin discontinuation rates up to 4 years post-
diagnosis and examined the factors associated with
statin discontinuation.
Results: The proportion of cancer patients
discontinuing statin therapy at 4 years (27%) was
comparable to the comparison cohort; however,
signiﬁcantly higher proportions of the cancer cohort
discontinued statins than the comparison cohort at 3,
6 and 12 months of follow-up (9.7% vs 7.4% at
12 months, respectively). More than 30% of cancer
patients who died were dispensed statins within
30 days of death. Discontinuation of statin
therapy in cancer patients was associated with
regionalised and distant disease spread at diagnosis
(p<0.001), older age (p¼0.006), upper
gastrointestinal organs and liver cancer (aHR 2.95,
95% CI 1.92 to 4.53) and cancer of the lung, bronchus
and trachea (aHR 1.99, 95% CI 1.32 to 3.00) and
poorer survival.
Conclusions: Medications should be rationalised at
the time of a cancer diagnosis, especially in the setting
of a poor prognosis. At least for some patients in our
cohort, statin therapy may be inappropriately
continued which adds unnecessarily to therapeutic
burden.
INTRODUCTION
There has been much debate about the clin-
ical and economic beneﬁts of prescribing
preventive medicines for patients with life-
limiting illness.
1e3 In the area of cancer, there
has been a particular focus on ‘futile’ drug
use in the setting of advanced disease where
median survival is relatively short and there is
little to no evidence demonstrating the
beneﬁts of drug treatments during antici-
pated survival times.
24 e6 Consequently,
there have been calls from the medical com-
munity to review and reduce the therapeutic
burden on patients with life-threatening
disease.
4e7
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ARTICLE SUMMARY
Article focus
- There is limited clinical guidance on managing
comorbid conditions after the diagnosis of life-
threatening illness.
- Some medications may be continued unneces-
sarily and may even cause harm after a cancer
diagnosis.
- The aim of this study is to examine the rates of
statin discontinuation in a cohort of older cancer
patients compared with their peers with no
cancer diagnosis.
Key messages
- In the setting of cancer, statins may be continued
unnecessarily in some patients.
- A high proportion of cancer patients are
dispensed statins 30 days before death.
- Reassessment of existing treatments is recom-
mended after a cancer diagnosis so as to
minimised therapeutic burden.
Strengths and limitations of this study
- This is a large retrospective cohort study of
elderly Australians using population data set
linkage.
- We were unable to establish if statin therapy had
been reviewed subsequent to a cancer diagnosis
nor the reasons for discontinuation.
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Open Access ResearchDespite the large body of evidence guiding clinicians
to initiate medications for the management of comorbid
conditions, there has been limited guidance on reducing
or ceasing medications at the end of life. Furthermore,
there is a scarcity of studies examining the management
of comorbid conditions after the diagnosis of life-
threatening illness. However, there is some evidence to
suggest that medications used for the secondary
prevention of comorbid disease are continued longer
than clinically indicated.
1 589
Statins are among the most commonly prescribed
medications in the developing world. Their beneﬁt in
reducing cardiovascular events and mortality after an
acute coronary syndrome, as well as the reduction in risk
of major cardiovascular events in people without estab-
lished cardiovascular disease is well documented.
10e13
However, many questions remain about the use of these
medicines with advancing age. In particular, competing
risks from cancer and other comorbid conditions, drug
interactions due to high levels of polypharmacy and
tolerability are likely to alter the beneﬁt/risk ratios in
older patients.
14e16
The aim of this study was to examine statin discon-
tinuation in a cohort of elderly cancer patients as
compared with a matched cohort of non-cancer
patients. We also assess the predictors of statin discon-
tinuation in cancer patients, including the effect of
spread of disease.
METHODS
Setting
The Pharmaceutical Beneﬁts and Repatriation Pharma-
ceutical Beneﬁts Schemes (PBS and RPBS) are national
programmes subsidising prescription drugs to the
Australian population and Australian Government
Department of Veterans’ Affairs (DVA) clients. The
RPBS comprises all PBS items plus additional items
available only to DVA clients.
17 18 In the Australian
setting, chronic medicines including statins are generally
prescribed as a month supply with ﬁve repeats.
19
Data sources and linkage
We used the following data sets to undertake our study:
1. DVA client ﬁle (1994e2007): information on sex,
dates of birth and death and veteran entitlement level
of DVA clients residing in New South Wales (NSW),
the largest Australian state.
2. RPBS (July 2004 to June 2009): all dispensed
pharmaceutical items (RPBS item code, name and
strength, date of supply, quantity supplied and
entitlement at time of dispensing).
3. NSW Central Cancer Registry (1994e2007): mandatory
notiﬁcations of invasive cancer in NSW. We used
International Classiﬁcation of Diseases for Oncology,
Third edition (ICD-O-3)
20 codes to identify cancer types.
4. Admitted Patient Data Collection (July 2000 to June
2009): all public, private and repatriation hospital
separations in NSW.
Data linkage was undertaken by the NSW Centre for
Health Record Linkage using best practice privacy
preserving protocols. The study was approved by the
NSW Population and Health Services and Department of
Veterans’ Affairs Human Research Ethics Committees
(approval numbers: 2008/02/060 and E008/003) and
did not require consent from individuals.
Cancer cohort (n[1731)
Comprised fully entitled clients aged 65 years or older,
with a primary invasive cancer notiﬁcation between 2005
and 2007, alive for at least 6 months post-diagnosis and
with at least two statin dispensing records (ATC codes
C10AA, C10BA, C10BX) in the 90 days prior to their
diagnosis date (at least one within 60 days). We used the
statin dispensing date immediately prior to diagnosis
date as the index date for follow-up.
Comparison cohort (n[3462)
Certain cancers are gender speciﬁc and age related.
21 22
Furthermore, statin discontinuation is age and gender
related by virtue of their relationship to cardiovascular
risk factors.
23 As such, we matched (using random
selection without replacement) two clients with no
evidence of a cancer notiﬁcation to every cancer cohort
member on year of birth (within 5 years), gender,
a statin dispensing record within 15 days of the index
date and ﬁrst statin dispensing date (within 15 days) to
match patients with comparable duration of statin
treatment. Cohort members also were alive for at least
6 months after the index date.
Statistical analyses
Differences between the characteristics of the cohorts
were examined using c
2 (likelihood ratio) test. Our
follow-up period commenced 60 days after the index
date until 31 December 2009. We deﬁned the discon-
tinuation date as the date of last dispensing plus 30 days.
We did not consider patients to have discontinued
therapy if this date was within 6 months of the end of
follow-up or in the 3 months before death. We calculated
proportion discontinued at various time-points using
KaplaneMeier product limit estimates. KaplaneMeier
overall survival curves were generated for cancer patients
who did and did not discontinue statins in the ﬁrst
6 months after diagnosis. Follow-up continued until the
last statin dispensing date before discontinuation, 31
December 2009 or death date.
We used Cox regression to compare discontinuation
between cohorts, stratifying by cancer patients matched
to their controls (prior hospitalisation was included as
a covariate due to difference between the cohorts after
matching). For the cancer cohort, we also used Cox
proportional hazard regression to determine the factors
associated with discontinuation following a cancer diag-
nosis; adjusting for year of birth, spread of disease, cancer
topography, hospitalisations prior to diagnosis, comor-
bidity burden and median statin daily quantity prior to
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Statin discontinuation and cancerdiagnosis. We calculated the median daily quantity as
([Tablet Strength 3 Quantity dispensed]/WHO Deﬁned
Daily Dose (DDD)
24)/days supplied] and comorbidity
using the Rx-Risk Index using counts of up to 42 general
drug categories (not including cancer drug categories)
using pharmacy claims data within 6 months prior to
a patient’s cancer diagnosis.
25 26 We omitted gender from
this model as some cancers are gender speciﬁc. However,
gender did not show a statistically signiﬁcant bivariate
association with discontinuation. Statistical signiﬁcance
was assessed at the p<0.05 (two-tailed) level.
RESULTS
Cohort characteristics
Approximately two-thirds of the cancer and comparison
cohorts were aged 75 years or older on 1 January 2005
and 72% were men. The most common cancer diagnoses
were prostate (23%), colorectal (17%) and melanoma of
the skin (14%). Most cancer patients were diagnosed
with localised (46%) or unknown spread (32%). The
cancer cohort had fewer hospital admissions in the year
prior to the index date than the comparison cohort
(92% of the cancer cohort with #4 separations; 84% in
the comparison cohort; likelihood ratio c
2¼85.6,
p<0.0001). Comorbidity burden was similar in both
cohorts with 78% having four to nine comorbidities
prior to the index date.
Statin use prior to the index date
More than 90% of both cohorts were prescribed ator-
vastatin, simvastatin or pravastatin alone. The median
daily quantity prior to the index date was at least 1 DDDs
per day for atorvastatin, pravastatin and rovastatin. The
median time between the ﬁrst statin dispensing to the
index date was approximately 600 days for both cohorts,
with 18% of the cancer cohort and 26% of the compar-
ison group having at least one period of at least 90 days
between dispensing records; median duration of breaks
in therapy were 136 and 142 days in the cancer and
comparison cohorts, respectively (table 1).
Statin discontinuation
Median follow-up time was 913 and 958 days for the
cancer and comparison cohorts, respectively (IQR
464e1297 and 496e1289 days). We found no signiﬁcant
differences in the discontinuation estimates of the cancer
and comparison cohorts after 4 years (cancer 26.5%
(95% CI 24.1% to 29.2%); comparison 27.2% (95% CI
25.3% to 29.1%), p¼0.34 log-rank test). A signiﬁcantly
higher proportion of cancer patients compared with the
comparison cohort discontinued statin therapy at 3, 6
and 12 months; however, after 12 months, the proportion
of the cancer and comparison cohort discontinuing
therapy was comparable (ﬁgure 1). More than 31% of the
cancer cohort who died had a statin dispensed within
30 days of their death (ﬁgure 2), and this was the case for
21% of those with metastatic disease and 35% with
localised spread at diagnosis.
Table 1 Statin use prior to (and including) index date of
cancer and comparison cohorts
Variable
Cancer cohort Comparison cohort
N[1731 N[3462
Statin type, n (%)
Atorvastatin
alone
685 (39.6) 1304 (37.8)
Fluvastatin
alone
13 (0.8) 39 (1.1)
Pravastatin
alone
257 (14.8) 525 (15.2)
Rosuvastatin
alone
1 (0.0) 3 (0.0)
Simvastatin
alone
653 (37.7) 1306 (37.8)
Two or more
statins
122 (7.0) 285 (8.2)
DDD/day, median
(IQR)
Atorvastatin 1.00 (1.0e2.00) 1.00 (1.00e2.00)
Fluvastatin 0.67 (0.33e0.67) 0.67 (0.33e0.67)
Pravastatin
sodium
1.33 (0.67e1.33) 1.33 (0.67e1.33)
Rosuvastatin 2.00 (1.00e2.00) 2.00 (1.00e2.31)
Simvastatin 0.67 (0.67e1.33) 0.67 (0.67e1.33)
Time from ﬁrst
statin to index date
(days), median
(IQR)
611 (336e901) 616 (339e903)
Patients with
breaks of
$90 days in
therapy, n (%)
310 (17.9) 888 (25.6)
Duration of breaks
in therapy (days),
median (IQR)
136 (102e211) 142 (104e232)
DDD, deﬁned daily dose.
Figure 1 Statin discontinuation after index date as
determined with KapleineMeier product limit estimates.
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Statin discontinuation and cancerPredictors of statin discontinuation
Cancer patients did not have signiﬁcantly different time
to statin discontinuation when compared with their
matched comparisons or was prior hospitalisation
a signiﬁcant factor (stratiﬁed Cox proportional hazard
regression: p¼0.56 and p¼0.96, respectively). For the
cancer cohort alone, older age and those diagnosed with
non-localised disease had shorter time to statin discon-
tinuation, as did patients with upper gastrointestinal and
liver cancer and cancer of the lung, bronchus and
trachea. Patients with melanoma of the skin had longer
times to discontinuation (ﬁgure 3).
Figure 4 further demonstrates the relationship
between statin discontinuation and prognosis; cancer
patients who had discontinued statin therapy within
6 months of diagnosis had poorer overall survival than
those who did not discontinue statin therapy within
6 months (log-rank p value <0.001).
DISCUSSION
This retrospective cohort study of elderly Australians
highlights a need for comprehensive and ongoing review
of medications after the diagnosis of life-limiting illness.
Our ﬁndings demonstrate that in the setting of cancer,
statins may be continued unnecessarily. We chose to
examine statins as they are only used for risk reduction
and the decision they should be discontinued when the
prognosis is poor is relatively straightforward. It is likely
that the variation in the practice observed in our study of
reconsidering medication use at the time of diagnosis
would be similar to that of other medications. In fact,
when the indication is less clear-cut, discontinuation may
be less likely to occur.
To complement the existing literature, which has
focused on statin discontinuation in the 6 months prior
to death, we examined statin discontinuation subse-
quent to a cancer diagnosis and found the proportion of
patients discontinuing therapy are relatively low in the
ﬁrst 12 months after a diagnosis but are higher than in
non-cancer patients. Beyond 12 months post-diagnosis
discontinuation, estimates were no different to those
in the non-cancer population and when compared
with each matched control, there was no difference
between cancer and non-cancer populations for time to
discontinuation.
Research in this area to date has focused exclusively on
cancer patients with end-stage diseases.
1 56However, our
methodological approach using a cohort of patients
diagnosed at all stages of disease demonstrates clearly
that there may be some recognition on the part of
doctors and/or patients that medications need to be
rationalised in light of a poorer prognosis. In our cohort,
statin discontinuation was associated with a diagnosis of
metastatic disease and poorer overall survival.
Figure 2 Scatter plot of time to
last statin prescription against time
to death from diagnosis date.
Shaded area indicates the period
within 30 days of death.
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Statin discontinuation and cancerNevertheless, a large proportion of cancer patients were
prescribed statins in the 30 days before death.
Our ﬁndings are consistent with previous research
from North America and Australia, all of which high-
light the missed opportunities to reduce the thera-
peutic burden of many patients after a life-limiting
diagnosis.
4e7 If the potential beneﬁts of therapy are
incremental and long term, then there are strong
imperatives for review when cancer therapies are
commenced as it is well established that the risks of
adverse outcomes increases exponentially with the total
number of medications (the ‘therapeutic burden’).
27
O u rs t u d yi sl i m i t e di nt h a tw ew e r eu n a b l et oe s t a b l i s h
the reasons for discontinuation in our cohort. However,
improved communication among physicians and
patients is likely to increase the understanding about
the original therapeutic goals of particular treatments.
Furthermore, more systematic guidance on ceasing
m e d i c a t i o n sa tt h ee n do fl i f ew o u l dr e d u c et h e r a p e u t i c
burden for individual patients and have the added
beneﬁt of reducing costs placed on already stretched
healthcare budgets.
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